Zynerba Pharmaceuticals Email Format

Pharmaceutical ManufacturingPennsylvania, United States2-10 Employees

Zynerba Pharmaceuticals develops and aims to commercialize transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders with high unmet medical need. Its lead candidate, Zygel, is a cannabidiol-based gel formulated to deliver CBD through the skin into the bloodstream. Transdermal delivery can reduce adverse effects associated with oral dosing by bypassing the gastrointestinal tract and first-pass metabolism, potentially enabling lower doses and a better safety profile. The company is evaluating Zygel in Fragile X Syndrome, 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder. 

Based in Devon, Pennsylvania, Zynerba operates in the pharmaceutical manufacturing sector. It maintains a small team and pursues a wholly-owned clinical development program centered on the indications noted above.

Get verified Zynerba Pharmaceuticals emails free

Company overview Employee directory